OBJECTIVE: Abundant evidence has demonstrated that long-term cytokine-mediated inflammation is a risk factor for obesity and type 2 diabetes mellitus (T2DM). Our previous study reveals a significant association between promoter polymorphisms of Th2-derived cytokine interleukin-4 (IL-4) and T2DM, which suggests possible roles of IL-4 in metabolism. In this study, we focused on examining the putative regulation of glucose and lipid metabolism by IL-4. METHODS: C57BL/6 mice were intraperitoneally injected with either adenovirus containing full-length IL-4 encoding gene (AdIL-4) or recombinant IL-4 for mimicking the status of transient and long-term IL-4 overexpression, respectively, and the effects of the overexpressed IL-4 to glucose/lipid metabolism and insulin sensitivity were subsequently investigated. Results: Our results reveal that IL-4 improves insulin sensitivity and glucose tolerance through upregulating Akt phosphorylation while attenuating GSK-3b activities. IL-4 is also involved in lipid metabolism by inhibiting lipid accumulation in fat tissues, which lead to decreased weight gain and fat mass. CONCLUSIONS: Our results suggest that IL-4 regulates glucose and lipid metabolism by promoting insulin sensitivity, glucose tolerance and inhibiting lipid deposits. This study uncovers the novel roles of IL-4 in metabolism and provides new insights in the interaction between cytokines/immune responses, insulin sensitivity and metabolism.
INTRODUCTION
Insulin resistance, the major cause of type 2 diabetes mellitus (T2DM), is occurred when insulin-target cells cannot effectively transduce insulin signaling and eventually become less sensitive to insulin stimuli. The consequences of impaired insulin signaling include reduced glucose uptake and disposal as well as increased hepatic gluconeogenesis. 1 In addition to T2DM, abundant evidence demonstrates that insulin resistance also has an important role in other metabolic abnormalities, such as obesity, dyslipidemia, hypertension and cardiovascular diseases. 2, 3 T2DM is a chronic inflammatory state of elevated circulatory proinflammatory cytokines, such as interleukin (IL)-1b, IL-6 and tumor necrosis factor-a. 4, 5 These increased cytokines act as negative regulators to modulate glucose homeostasis and contribute as a link between immune responses and T2DM. Excessive intake of glucose and macronutrients also induce oxidative stress and cytokine mediators, which subsequently block insulin signaling. 6--10 Triacylglycerols storage in adipose tissues is impaired by chronic inflammation, which leads to the elevation of circulating free fatty acids (FFAs) and triacylglycerols, and eventually insulin resistance. 11 Accordingly, cytokines are associated with systemic insulin resistance, metabolic diseases and diabetes. Therefore, it is tempting to determine whether other cytokines are also involved in the pathogenesis of T2DM.
IL-4 is a pleiotropic cytokine secreted by activated Th2 cells, FceR1 þ cells and eosinophils. IL-4 has an important role in inflammatory reactions by modulating growth, differentiation and cytokine production. 12 Although IL-4 signaling is known to trigger phosphorylation of insulin receptor substrate 2, 13,14 chronic insulin and glucose treatment attenuates IL-4-dependent insulin receptor substrate 2 phosphorylation. 15 It suggests that IL-4 can positively regulate insulin signaling pathway. In addition, our recent study reveals a significant association between IL-4 genotypes and T2DM. 16 Nevertheless, the influence of IL-4 on metabolism has not been extensively addressed and deserves further investigation. In this context, this study aimed at investigating in vivo effects of IL-4 on metabolism using mice T2DM model induced by single lowdose streptozotocin (STZ) administration and high-fat diet (HFD). 17--20 Our results show that IL-4 overexpression leads to better glucose utilization. In addition, body weights and fat mass of mice with IL-4 treatment are significantly lower than their counterparts. These observations suggest that IL-4 is involved in mediating glucose and lipid metabolism.
MATERIALS AND METHODS

Cell culture and adenovirus expansion
Human AD293 embryonic kidney cells were cultured in Dulbecco's modified Eagle's medium containing glucose (4.5 g l --1 ) and 10% fetal bovine serum. Recombinant adenoviruses expressing IL-4 (AdIL-4) and bgalactosidase (AdLacZ, as a negative control) were kindly provided by Dr Nagayama. 21 AdIL-4 and AdLacZ were respectively propagated in AD293 cells and purified by cesium chloride density gradient ultracentrifugation, followed by dialysis in phosphate-buffered saline with 10% glycerol. Number of viral particles was determined by measuring the absorbance at 260 nm.
Animal experiments
All mice were obtained from National Laboratory Animal Center and caged in groups of five. For adenovirus experiments, 8-week-old male C57BL/6 mice were intraperitoneally (i.p.) injected twice (once daily for 2 consecutive days) with 5 Â 10 11 particles of AdIL-4 or AdLacZ. The adenovirus-injected mice were i.p. administered with STZ (100 mg kg --1 ; Sigma-Aldrich, St Louis, MO, USA) on the second day. 21 Intraperitoneal glucose tolerance test (IGTT), intraperitoneal insulin tolerance test (IITT) and circulatory biochemical parameters were assessed on the third day. For long-term IL-4 administration experiments, 4-week-old C57BL/6 mice were fed with HFD (60% kcal) or standard diet (SD), and i.p. administered with IL-4 (1000 pg per mouse; BD Pharmingen, Franklin Lakes, NJ, USA) every other day for 8 weeks. Then the mice were killed after IGTT, IITT and biochemical tests were performed. In IL-4 neutralization experiments, BALB/c mice with relatively high IL-4-secreting ability were used instead of low IL-4-secreting C57BL/6 mice. 22 Four-week-old male mice were first fed with SD or HFD for 10 weeks, then divided to four groups: (1) SI group received i.p. STZ-injection followed by IL-4 antibody administration on the second, third and fifth day (50 mg per mouse; Biosource, Camarillo, CA, USA); (2) IS group received IL-4 antibody administration on the first, second and fifth day, and STZ injection on the third day; (3) STZ group received only STZ treatment on the first day; and (4) Control group received citrate buffer (0.05 M, pH 4.5; USB, Cleveland, OH, USA) administration. Then the mice were killed after IGTT, IITT and biochemical tests were performed. Animal protocols were reviewed and approved by the Chung Shan Medical University animal studies committee.
IGTT, IITT and blood parameters IGTT was performed and blood glucose was measured using OneTouch monitoring system (LifeScan Taiwan, Taipei, Taiwan) before and after i.p. glucose injection (2 g kg --1 ; Sigma-Aldrich, Steinheim, Germany) at the indicated time. IITT was conducted and blood glucose was monitored at the time points indicated after i.p. injection of recombinant human insulin (1 U kg --1 ; Eli Lily, Indianapolis, IN, USA). Serum levels of insulin (Mercodia, Uppsala, Sweden), IL-4 (R&D, Minneapolis, MN, USA), leptin (Millipore, Billerica, MA, USA), adiponectin (Millipore) and FFA (BioVision, Mountain View, CA, USA) were measured after overnight fast using enzyme-linked immunosorbent assay kits according to the manufacturer's instructions. The epididymal fat pads were taken and weighted, and the adipocytic cross-sectional areas from staining images were calculated.
Western blot
Protein extracts from muscle and epididymal fat tissues were obtained after the tissues were homogenized using T-PER tissue protein extraction reagent (Pierce, Rockford, IL, USA) supplied with phosphatase and protease inhibitors (Roche, Indianapolis, IN, USA). Protein lysates were normalized using Bio-Rad (Hercules, CA, USA) protein reagent and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then electrotransferred to polyvinylidine fluoride membrane. The membranes were blocked and incubated with mouse anti-actin monoclonal immunoglobulin G (Abcam, Cambridge, UK), mouse anti-phospho-Akt serine 473, rabbit anti-Akt, rabbit anti-phospho-GSK3b serine 9 and rabbit anti-GSK3b, respectively. All primary antibodies were purchased from Cell Signaling (Danvers, MA, USA), except where otherwise indicated. Then, membranes were incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies. Results were developed using ECL reagents and quantitated by densitometer. All secondary antibodies and ECL reagents were purchased from Millipore (Temecula, CA, USA).
Statistical analysis
Results were presented as mean ± s.e.m. and the significant difference between groups was analyzed by one-way or two-way analysis of variance using SPSS software (NY, USA). Statistical difference was defined as Po0.05 for all test.
RESULTS
Effects of in vivo IL-4 overexpression on glucose metabolism
To establish a mouse model with high IL-4 levels, 8-week-old C57BL/6 mice were first subjected to i.p. injection with AdIL-4, followed by STZ treatment (AdIL-4 mice). Mice with either citrate buffer (control mice) or AdLacZ administration and STZ treatment (AdLacZ mice) were served as controls. Serum IL-4 level of AdIL-4 mice (10.16±1.72 pM) was significantly higher than that of control (1.17 ± 0.44 pM) and AdLacZ (1.64 ± 0.65 pM) mice (Table 1) . It indicated that the adenovirus administration can successfully turn the low IL-4-secreting C57BL/6 mice into high IL-4-expressing animal model. Biochemical parameters including adiponectin, leptin, insulin and FFA were then analyzed to examine the effects of in vivo IL-4 overexpression on metabolism. As listed in Table 1 , levels of adiponectin, leptin and insulin were all significantly increased in AdIL-4 mice. AdIL-4 mice had higher FFA levels, however, this difference did not reach statistical significance.
The effects of IL-4 overexpression on glucose homeostasis and insulin sensitivity were subsequently examined. The results showed that IGTT curves from control and AdLacZ mice were quite similar (Figure 1a) . Whereas, AdIL-4 mice demonstrated better glucose tolerance with a lower peak glucose level (approximately 13.89 mM) and a shorter time required for reaching glucose homeostasis (about 90 min). Consistent with the IGTT observations, IITT results showed that insulin sensitivity and glucose tolerance of AdIL-4 mice were significantly better than that of control and AdLacZ mice (Figure 1b) . Effects of IL-4 neutralization on glucose metabolism To verify the above observations, high IL-4-producing BABL/c mice were used to examine if the effects of IL-4 on metabolism could be reversed by depleting IL-4. BALB/c mice were first fed either with SD or HFD for 10 weeks, and their IL-4 bioactivities were neutralized before or after STZ treatment as described in Materials and methods section. IGTT results showed that blood glucose of all the mice groups with SD reached the peak levels at about 30B40 min, with high glucose levels sustained till 120 min in SI, IS and STZ mice (Figure 1c) . Interestingly, blood glucose levels in mice with IL-4 neutralization (SI and IS) were consistently and significantly higher than mice without IL-4 depletion (control and STZ; Figure 1c ). Similar phenomena were also observed in HFD-fed mice: glucose levels in mice with IL-4 neutralization remained high still 120 min after glucose injection, compared with control and STZ mice groups (Figure 1d ). These data suggested that mice with IL-4 overexpression had better glucose tolerance and metabolism.
Effects of in vivo IL-4 on Akt and GSK3b phosphorylation To further examine the mechanism of IL-4 promoting glucose tolerance, influences of IL-4 to the activity of the insulin downstream signaling mediators, Akt and GSK3b, were explored. Akt phosphorylation were significantly increased in muscle cells of AdIL-4 mice; whereas, no significant alterations of Akt phosphorylation were observed in epididymal fat (Table 2 ). It suggests that the IL-4-improved glucose tolerance might result from enhancing insulin action by upregulating Akt activities in muscle cells. On the contrary, levels of phosphorylated GSK3b were decreased in AdIL-4 mice ( 
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0.47 ± 0.10 nM), compared with mice without IL-4 treatment (control, 0.49 ± 0.09 nM; HFD, 0.82 ± 0.11 nM; Table 1 ).
Interestingly, body weights and fat mass of mice with IL-4 treatment (IL-4 and HFD þ IL-4 mice) were significantly lower than the counterparts without IL-4 injection ( Figure 2a and Table 3 ; with the original data of Figure 2a listed in Supplementary Table  S1 ). Weights of the epididymal fat pads were decreased in IL-4-treated mice (IL-4, 0.16 ± 0.02 g; HFD þ IL-4, 0.92 ± 0.31 g), compared with the mice without IL-4 treatment (control, 0.28 ± 0.03 g; HFD, 1.08±0.09 g; Table 3 ). The adipocytic cross-sectional areas in IL-4-treated mice were significantly smaller (with relative ratio to control mice: IL-4, 0.61 ± 0.03; HFD, 1.19 ± 0.05; HFD þ IL-4, 1.01 ± 0.06; Table 3 ). The same phenomenon was also observed in epididymal adipocytes of AdIL-4 administered mice (with relative ratio to control mice: AdLacZ, 1.03±0.11; AdIL-4, 0.66 ± 0.07; Table 3 ). Taking the results of decreased fat mass and the increased serum FFA levels (Table 1) (Figure 2b) . Similarly, the IITT results showed that insulin sensitivity and glucose tolerance of IL-4-treated mice were significantly better than that of the corresponding control mice (Figure 2c ).
Effects of long-term IL-4 treatment on Akt and GSK3b phosphorylation
The Akt phosphorylation was significantly decreased in muscle of HFD þ IL-4 mice; nevertheless, it was dramatically increased in the epididymal fat of IL-4 and HFD þ IL-4 mice ( Table 2) . It suggested that under long-term IL-4 treatment, the improved glucose tolerance and insulin sensitivities might result mainly from the enhanced insulin action by upregulating Akt activities in fat tissues. The levels of phosphorylated GSK3b were significantly decreased both in the muscle and fat tissues of IL-4 and HFD þ IL-4 mice, comparable to the results from adenovirus experiments, (Table 2) . DISCUSSION T2DM is associated with chronic inflammation. Although the correlation between IL-6/tumor necrosis factor-a and insulin resistance has been extensively studied, 23--25 relatively few are known about the roles of other cytokines in diabetic pathogenesis. IL-4, another cytokine secreted by Th2 cells, participates in the regulation of inflammation by modulating expression of other pro-inflammatory cytokines and inflammation mediators. 26, 27 This Abbreviations: AU, arbitrary unit; HFD, high-fat diet; IL, interleukin. *Data are presented as mean ± s.e.m., which indicate the relative ratios of crosssectional areas (AU) using that from corresponding control mice as control. study uncovers the roles of IL-4 in glucose/lipid metabolism and insulin sensitivity using animal model. In AdIL-4 experiments, our results suggest that transient IL-4 treatment improves glucose tolerance and insulin sensitivity (Figures 1a and b) . This effect is also observed in the IL-4 neutralization experiments, in which glucose tolerance and insulin sensitivity are exacerbated in mice injected with IL-4 antibodies (Figures 1c and d) . In mice with long-term exposure to high IL-4 levels, the capacity of IL-4 to promote glucose tolerance and insulin sensitivity is further confirmed (Figure 2) . Interestingly, while Akt phosphorylation is significantly induced in muscle of mice with transient IL-4 treatment, it is significantly induced in fat cells of mice with long-term IL-4 exposure ( Table 2) . It indicates that better glucose tolerance and insulin sensitivity under IL-4 treatment may be resulted from its capacity to promote insulin signaling.
In addition to the roles in promoting insulin signaling, the observation that insulin levels are significantly increased in AdIL-4 mice ( Table 1) (Table 2 ) support the previous evidence that IL-4 mediates glucose metabolism by regulating glycolytic enzymes. 28, 29 It is intriguing that IL-4 promotes glucose tolerance through activating Akt activities while suppressing GSK3b phosphorylation. There are two possible explanations to this contradictory observation. First of all, IL-4 might display differential regulatory function to different insulin-targeted organs for maintaining metabolic hemeostasis. The reduced GSK3b activities in muscle and fat tissues might not be applied to liver, the critical target organ of glycogen synthesis. Besides, a recent study reveals that fibroblast growth factor 19 facilitates postprandial hepatic protein and glycogen synthesis through an insulin-independent pathway. 30 Therefore, the downregulated GSK3b activities in fat and muscle cells may not represent that glycogen synthesis is suppressed in hepatocytes. Second, this contradictory regulatory effect of IL-4 might be in response to the increased energy needs from cells to maintain homeostasis for avoiding cellular apoptosis, as previous described. 31 Production of the pro-inflammatory cytokine IL-6 is essential to induce glucose intolerance and insulin resistance. 25 Lee et al. 32 reveals that the genetic inactivation of PKCz leads to a hyperinflammatory state with increased synthesis of pro-inflammatory cytokine IL-6 in obese mice, which are more glucose intolerant and insulin resistant. Their study shows that PKCz is a critical negative regulator of IL-6 in the control of obesity-induced inflammation because the glucose intolerance and insulin resistance phenotypes are corrected to normal by silencing IL-6 expression in PKCz-deficient mice. The positive regulatory role of IL-4 to glucose tolerance and insulin sensitivity uncovered by this study is consistent to the conclusion from Lee et al. 32 because PKCz serves as a critical role in the anti-inflammatory effects of IL-4.
33,34 Accordingly, it supports our hypothesis that the positive regulatory role of IL-4 to glucose tolerance and insulin sensitivity may originate from its anti-inflammatory function by inhibiting the production of cytokines inducing insulin resistance, such as tumor necrosis factor-a and IL-6. 35 Our results also suggest that IL-4 participates in lipid metabolism by regulating the circulatory levels of adiponectin and leptin. Intriguingly, adiponectin and leptin levels are both elevated under transient IL-4 treatment; whereas leptin levels are significantly decreased in HFD mice with long-term IL-4 administration. In addition, serum FFA levels are both increased after IL-4 treatments ( Table 1) . These data further support the capacity of IL-4 to promote insulin sensitivity and glucose metabolism because adiponectin has been shown to elevate insulin sensitivity and inhibit hepatic gluconeogenesis. 36 However, the inducing ability of IL-4 to b-cell insulin secretion is not observed in long-term IL-4 experiments, discrepancy in leptin levels is also observed in mice with different duration of IL-4 treatment (Table 1) . Elevated levels of leptin and IL-4 in rats with acute pancreatitis are reported for increasing pancreatic resistance against inflammatory damages.
37
The increased levels of leptin in transient IL-4-treated mice support the suggestion of the above study, whereas, the food intake (for example, HFD in this study) has a dominant role in regulating leptin secretion. We suggest that the absence of induced insulin and leptin secretion under long-term IL-4 administration might be an adaption to the consistently elevated cytokine exposure for maintaining insulin levels and homeostasis.
The weekly weight gain in the IL-4-treated mice is lower (IL-4 and HFD þ IL-4; Figure 2 and Supplementary Table S1 ), moreover, long-term IL-4 treatment leads to a reduction of fat mass and the cross-sectional areas of fat cells ( Table 2) . As evidence has revealed that leptin secretion is positively correlated with the amount of adipose tissues, 38 and adiponectin concentrations are reduced as adiposity increases, 39, 40 we suggest that the significantly slower weight gain might result from the increased lipolysis in fat cells, which leads to the elevated circulatory FFA in IL-4-treated mice. Although the exact underlying mechanisms await further investigation, our results support the previous report that IL-4 transgenic mice contain less and smaller sized dermal fat tissues. 41 Our data also support another study in which documents that IL-4 secretion and Akt activity are both promoted in fatless A-ZIP/F1 diabetic mice. 42 In summary, overexpression of IL-4 may promote glucose tolerance and insulin sensitivity through boosting insulin signaling by altering Akt and GSK3b activities. IL-4 is also involved in lipid metabolism by regulating adipokines and FFA levels. We suggest that IL-4 regulates metabolism by promoting insulin sensitivity, glucose tolerance and inhibiting lipid deposits. This study reveals evidence to uncover the novel roles of IL-4 in metabolism, and provide new insights in the interaction between cytokines/ immune responses, insulin sensitivity and metabolism.
